Sarah Walbolt/LinkedIn
Aug 20, 2026, 13:15
Sarah Walbolt: Study Findings Challenge Long-Term Anticoagulation
Sarah Walbolt, Program Manager at University of Utah Health, Chief Executive Officer Sanguine Health Holdings Inc, shared a post LinkedIn about a recent article by Sabine Eichinger et al., published in Blood Advances, adding:
”Terminated study due to risk: Findings challenge current treatment paradigms and support individualized decisions regarding anticoagulation duration.
Would love your thoughts!”
Title: Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study
Authors: Sabine Eichinger, Lisbeth Eischer, Alexandra Kaider, Georg Heinze, Peter Quehenberger, Paul A. Kyrle
Stay updated on the latest scientific advances with Hemostasis Today.
-
Aug 20, 2026, 15:15The Cell in Your Bone Marrow Responsible for Making Platelets – ITP Support Association
-
Aug 20, 2026, 15:10Shiny K. Kajal: The Latest ISBT Blood Group Update Is Here
-
Aug 20, 2026, 14:57Spiros Denaxas: The Risk Factor Paradox in Recurrent Heart Disease
-
Aug 20, 2026, 14:44ISTH SSC Women’s Health Survey: Thromboprophylaxis in Pregnancy
-
Aug 20, 2026, 14:22Wolfgang Miesbach։ Thrombosis After Haemophilia B Gene Therapy
-
Aug 20, 2026, 14:08Ahmed Mostafa: Decoding HLA-B27 in Ankylosing Spondylitis
-
Aug 20, 2026, 14:02Rafail A. Kotronias: Improving the Detection and Management of Coronary Microvascular Obstruction
-
Aug 20, 2026, 14:00Cindy Neunert: What Matters Most to Patients with ITP
-
Aug 20, 2026, 13:46Mario Enrico Canonico։ CLEAR Outcomes Analysis Highlights Bempedoic Acid Benefits in PAD